Kornimate/medical-research-clean huggingface dataset:
the clinical efficiency of tb-era in chinese rif patients

Conditions: Endometrial Receptivity; Repeated Implantation Failure

Summary: in order to further explore the clinical utility of endometrial receptivity array in patients with repeated implantation failure, the patients divide into the experimental group or the control group. in the experimental group, those patients undergo endometrial receptivity array. in the control group, those patients do not receive any treatment before next cycle of transfer. in the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. statistical analysis of the two groups of primary endpoint and secondary endpoint are done.

in the field of assisted reproduction techonology, there are still 10% of patients with repeated implantation failure. in order to further explore the clinical utility of endometrial receptivity array in patients with repeated implantation failure, the patients divide into the experimental group or the control group. in the experimental group, those patients undergo endometrial receptivity array. in the control group, those patients do not receive any treatment before next cycle of transfer. in the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. in the control group, no intervention will be performed. statistical analysis of the two groups of primary endpoint (clinical pregnancy rate) and secondary endpoint (endometrial implantation window evaluation results, embryo implantation rate, biochemical pregnancy rate, early abortion rate, ectopic pregnancy rate) are done. through the comparative analysis of clinical outcomes to verify the clinical efficacy of endometrial receptivity analysis in patients with repeated implant failure, this method will provide a new treatment for repeated implant failure population.

Eligibility criteria:
inclusion criteria: 1. people with unexplained repeated implantation failure (3 or more times of transplantation, at least 4 or more high-quality embryos failed to conceive). 2. age: 20-40 years old. 3. bmi: 19 - 24. 4. the thickness of endometrium is more than or equal to 7 mm. exclusion criteria: 1. known causes of embryo implantation failure, such as infection, reproductive tract malformation, uterine cavity factors, immune factors, hydrosalpinx, etc. 2. decreased ovarian function (meet the following at least two criteria: ① 10u / l \ 292.8pmol/l, and / or fsh / lh \> 3; ② the number of antral follicles \< 5-7 on the second to third day of menstruation; and (or) antimullerian hormone (amh) \< 0.5-1.1ng/ml. 3. people with genetic history. 4. those who have done abortion and the histogenetic analysis are positive.

Keywords: endometrial receptivity array repeated implantation failure
parents information in child rehabilitation

Conditions: Children with Chronic Condition

Summary: in france, approximaly 3 million children have a chronic disease and require regular care such as paediatric rehabilitation. these cares are provided over long periods of time, most often throughout childhood and often into adulthood. paediatric rehabilitation care involves multidisciplinary team working closely with families. during follow-up rehabilitation, communication between the children, families and the professionals is essential. to this end, digital health solutions can be helpful. digital health solutions are rapidly emerging in the field of paediatric rehabilitation. in this context of emergence of digital health solutions, it is essential to identify the needs and expectations of families of children with a chronic disease. this project aims to identify the key points in terms of information exchange on rehabilitation monitoring. to identify these needs, a mixed study will be carried out from june 2022 to june 2023 involving focus groups to gather qualitative informations on parent's needs in terms of information exchange through digital apps and quantitative research with a survey that will allow to prioritise these needs.

for the first part of the study, the researchers will conduct focus groups and interview parents about their experiences and perceptions of information exchange with rehabilitation professionals. all the participants will be parents of a child with a chronic disease, aged between 0 and 18 years and receiving paediatric rehabilitation care. the objective of this first part is to collect qualitative information on the needs of parents in terms of information exchange through digital applications. with the analysis of the focus group, the researchers will define the hypothesis. then, a survey will be built and shared online in france during 3 months (2nd semester 2022). with this survey, the objective is to identify the key points for the development of paediatric rehabilitation apps in terms of information exchange. quantitative data will be described with frequency, mean and standard deviation.

Eligibility criteria:
inclusion criteria: - parents of a child (0-18 years) with a chronic condition and with a rehabiilitation follow up exclusion criteria: * parents who do not speak french * parents with an intellectual disability (for the first part : focus group)

Keywords: m-health mobile apps chronic disease informations parents pediatric rehabilitation communication
a phase i study to assess novel ointment in a psoriasis plaque test

Conditions: Psoriasis

Summary: to investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations of an2728 in patients with psoriasis vulgaris

the study will be performed in 12 male subjects with stable psoriatic plaques. the study preparations and the comparators will be tested observer-blind. treatments will be randomly assigned to the test fields. all subjects will receive all treatments, with intraindividual comparison of the treatments. altogether six test fields will be examined per subject (three active an2728 ointments of different concentrations: 5 %, 2 % and 0.5 %, the active ingredient-free vehicle, a marketed corticoid preparation and a marketed topical immunomodulator). the test fields will be treated occlusively over a study period of 12 days. a topical application of approximately 200 ul of each assigned intervention will be administered per treatment, for a total of 10 treatments over a 12-day treatment period.

Eligibility criteria:
inclusion criteria: * male subjects aged 18 years or older; * subjects with psoriasis vulgaris in a chronic stable phase and stable plaques with an area sufficient for six treatment fields; * the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study; * written informed consent obtained. exclusion criteria: * subjects who require systemically acting medications for the treatment of psoriasis, which might counter or influence the study objectives, e.g. corticosteroids, cytostatics; * local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4 weeks preceding and during the study (corticosteroids 8 weeks); * systemic treatment with antipsoriatics in the three months preceding and during the study; * treatment with systemic or locally acting medications which might counter or influence the study aim (e.g. glucocorticosteroids, mao inhibitors, anti-epileptic drugs, anti-psychotic drugs) or medications which are known to provoke or aggravate psoriasis, e.g. β-blocker, antimalarial drugs within two weeks before the beginning of the study and during the study; * known allergic reactions to the active ingredients or other components of the study preparations or comparators; * evidence of drug abuse; * uv-therapy within four weeks before beginning and during the study; * symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study; * participation in another clinical trial involving pharmaceutical products in the four weeks preceding and during the study; * in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent. * subject is institutionalized because of legal or regulatory order.

Keywords: plaque type psoriasis topical
robotic pedaling therapy for targeted neural plasticity

Conditions: Stroke

Summary: the aim of this pilot study is to determine whether robotically targeted lower-limb pedaling therapy can increase the extent of stroke recovery on behavioral measures and induce brain plasticity as measured by functional magnetic resonance imaging (fmri). forty (40) adult stroke patients and 80 healthy controls will be enrolled in this study. of the 40 patients, half will be randomly assigned to the robotically-targeted training ("robotic") group and will receive training on the targeted training task. the other half of the patients will perform a duration-matched aerobic pedaling exercise ("control" group). all stroke patients will be scanned before and after their training program while performing or imagining simple motor tasks. behavioral assessments of motor and cognitive capacities will be collected at each timepoint. healthy control subjects enrolled for device testing (20) will receive up to 5 training sessions in a modified robotic paradigm and 1 fmri scan, in order to investigate motor learning and brain activity in a novel motor control task. additional healthy pilot subjects (up to 60) will test training protocols and assessments during preparatory design phases of the project.


Eligibility criteria:
patients: inclusion criteria: * subjects will be stroke patients with persistent moderate unilateral lower extremity deficits, age 50-85 years at time of enrollment. * time since stroke will be greater than 6 months ("chronic" stroke survivors). * persistent moderate unilateral lower-limb impairment (defined as nih stroke scale - motor leg section score of 1-2, to be discussed with the patient verbally during phone screening and assessed by the investigator during the initial enrollment visit). * fluent in spoken and written english exclusion criteria: * allergy to electrode gel, surgical tape and metals. * subjects under treatment for infectious diseases will be excluded from the study. * women who are pregnant or planning to become pregnant during the course of the study will be excluded. * contraindications for mri * age over 85 years at time of enrollment. healthy controls: inclusion criteria: * ages 18-85 years * non-stroke group 1 ("matched controls"): 50-85 years old at time of enrollment, to match the population of stroke patients to be studied * non-stroke group 2 ("pilot controls"): 18-50 years old at time of enrollment (pilot subjects to be initially enrolled early in the design phase of the study, and with enrollment ongoing throughout the study to continue development.) * no known neurologic, psychiatric or developmental disability. * fluent in spoken and written english exclusion criteria: * allergy to electrode gel, surgical tape, and metals. * subjects under treatment for infectious diseases will be excluded from the study. * women who are pregnant or planning to become pregnant during the course of the study will be excluded. * contraindications for mri * age over 85 years at time of enrollment.
comparison of erector spinae plane block with thoracic paravertebral block for breast surgery

Conditions: Postoperative Pain; Breast Cancer

Summary: postoperative analgesia in breast surgery is a difficult and overworked issue due to etensive surgery and complex innervation of the breast. erector spinae plane block (esb) is a new defined and promising regional anesthesia technique for thoracic analgesia. main purpose of this study is to compare the analgesic effect of ultrasound guided esb with thoracic paravertebral block - the golden standard method for postoperative regional analgesia technique in breast surgery.


Eligibility criteria:
inclusion criteria: * 25-70 years of agge * asa i-ii * undergoing elective breast cancer surgery exclusion criteria: * obesity (body mass index \>35 kg/m2) * infection of the skin at the site of needle puncture area * patients with known allergies to any of the study drugs * coagulopathy * recent use of analgesic drugs

Keywords: erector spinae plane block thoracic paravertebral block breast surgery postoperative pain
preventing diabetic osteoporosis with exercise

Conditions: Diabetes Mellitus, Type 2

Summary: the two specific aims of the study were to determine whether: 1. greater mechanical loading of downhill exercise will increase the osteogenic index (ratio between cicp, the marker of bone formation (c-terminal propeptide of type i collagen, and ctx, the marker of bone resorption (c terminal telopeptide of type i collagen)) to a greater extent than uphill exercise that provides lower ground-reaction force; 2. exercise after the meals will induce greater osteogenic response than exercise pefore the meals as it is known that meal eating during daytime inhibits bvone resorption markers.

the study addresses the problem that postmenopausal women with type 2 diabetes have a higher incidence of bone breaks despite their often normal bone mineral density (bmd). the investigators pursued two hypotheses, that: 1. 40-minute bout of downhill exercise will increase the cicp/ctx osteogenic index to a greater extent than the same amount of uphill exercise; and 2. performing exercise one hour after the meals will be more osteogenic than exercise before the meals. subjects were 15 postmenopausal women with type 2 diabetes, age 57.7 years, bmi 27.2 kg/m2 who were randomly assigned to two out of 5 trials: uphill exercise before the meals (ubm), uphill exercise after the meals (uam), downhill exercise before the meals (dbm), downhill exercise after the meals (dam), and sedentary, no-exercise, trial (sed). all subjects signed an informed consent approved by the university of michigan medical school institutional review board. subjects had their bmd measured with dxa at the outset. weight-maintenance meals contained 50% carbohydrate, 15% protein, and 25% fat and were provided at 10 h and 17 h. exercise (40 minutes at 50% of maximal effort) on either uphill (+6o slope) or downhill treadmill (-6o slope) was performed either before the two meals, at 9 h and 16 h, respectively, or after the meals. at 11 h and 18 h, respectively. blood was drawn through an intravenous catheter from ante-cubital vein at hourly intervals between 8 and 20 h with two additional blood draws at 0 h and 6 h the next morning. blood was treated with protease inhibitors, and plasma, frozen at -80o c, was used to measure bone markers, cicp, ctx, osteocalcin , and bone-specific alkaline phosphatase using millipore chemoluminescen reagents, glucose by glucose oxidase, and hormones insulin, cortisol, parathyroid hormone (pth) , and growth hormone (gh) by radio-immunoassays.. mixed-model anova was used for analysis of outcome measures where the trial procedures served as fixed variable and individual subjects as intercept variables.

Eligibility criteria:
inclusion criteria: postmenopausal type-2 diabetes melllitus age between 50 and 65 exercise less than 20 minutes three times a week exclusion criteria: metabolic disease other than type-2 diabetes and hormonally-corrected hypothyroidism musculo-skeletal disability that would preclude exercise smoker do not meet inclusion criteria
graves' disease induced by epstein-barr virus lytic reactivation

Conditions: Graves Disease; Graves' Disease in Remission; Epstein-Barr Virus

Summary: previous studies have proved that the lytic reactivation of latent epstein-barr virus (ebv) was significantly associated with the onset of graves'disease (gd), however, the morbidity of gd and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of ebv is not understood. we will recruit patients with newly diagnosed gd and recurrence of hyperthyroidism after antithyroid drugs treatment. in order to confirm lytic reactivation of ebv, the number of ebv dna copies，mrna and protein expression of immediate-early, early and late lytic ebv genes，ebv +trab+cells will be tested. the proportion of lytic reactivation of ebv in newly diagnosed gd and recurrence of hyperthyroidism was evaluated.

the lytic reactivation of latent ebv play importment roles in development of gd and recurrence rate of hyperthyroidism. the aim of this study is to evaluate the proportion of lytic reactivation of ebv in newly diagnosed gd and recurrence of hyperthyroidism. all patients satisfied the diagnostic criteria for gd. the diagnotic remission of hyperthyroidism was included of clinical symptoms and elevated ft3 and ft4, the patients who have been received antithyroid drugs (methimazole or propylthiouracil) titration treatment for 18 or more months and of antithyroid drugs titration treatment and withdrawal antithyroid drugs at least 3 months. the evaluation of lytic reactivation of latent ebv including ebv dna copies，mrna and protein expression of immediate-early, early and late lytic genes，and ebv +trab+cells. the ebv dna copies was tested with pcr, mrna and protein expression of immediate-early, early and late lytic ebv genes were analysed with rt-qpcr or western blot and ebv +trab+cells were evaluated with flow cytometry. all statistical tests were performed using graphpad prism v8.0.

Eligibility criteria:
inclusion criteria: * the clinical evaluation included patient history, physical examination, and thyroid ultrasonography. laboratory and diagnostic testing included determination of serum levels of free thyroxine (ft4), t3 ( ft3), thyrotropin (tsh), tpoab, tgab, and serum levels of thyrotropin receptor antibody (trab). exclusion criteria: * patients with subacute thyroiditis, hyperfunctioning thyroid nodules, iodine hyperthyroidism, drug-induced hyperthyroidism, or other causes of hyperthyroidism were also excluded. the exclusion criteria for both patients with gd included diabetes, infectious diseases, other chronic diseases, and cancer.

Keywords: graves disease relapse of hyperthyroidism epstein-barr virus lytic reactivation morbidity
thrombosis and haemorrhage in chronic hemodialysis patients

Conditions: Chronic Renal Failure

Summary: the study t2hd "thrombosis and haemorrhage in chronic hemodialysis patients" is a study of pharmacoepidemiology observational, retrospective cohort, multicenter including 12 dialysis centers for adults lorraine. the main objective is to : describe the prescribing practices of drugs anticoagulants and antiplatelet agents in chronic hemodialysis patients in the lorraine region. the second objective is to : study the impact of these practices on the survival and the occurrence of major clinical events, thrombotic and hemorrhagic.

all adult patients aged 18 and over who started a new hemodialysis replacement therapy in lorraine between 01/01/2009 and 31/12/2010 are identified from the registry rein (epidemiology and information network in nephrology). the latter are included in the study t2hd to the initiation of dialysis and followed until the date point 30/06/2013. the outcome was survival without major clinical event. are considered major clinical events: acute coronary syndrome, acute limb ischemia, deep venous thrombosis, arterial thrombosis, pulmonary embolism, thrombosis first, ischemic or hemorrhagic stroke, the digestive hemorrhage, and severe bleeding. statistical analysis will compare event-free survival of patients in 4 groups. patients will be censored at the time of the occurrence of a kidney transplant, a dialysis method of change, a dialysis withdrawal, a move outside lorraine, or date point if they are still alive . to minimize bias maximum indication, patients of different groups will be matched on propensity score (probability for a given patient to be treated by antiplatelet and / or anticoagulant).

Eligibility criteria:
inclusion criteria: * male or female aged 18 and over, * in end-stage renal disease, * initiating a first hemodialysis replacement therapy in lorraine between 01/01/2009 and 31/12/2010. exclusion criteria: * evolutionary neoplasia at start of dialysis, * death within 45 days of the start of dialysis.

Keywords: dialysis thrombosis haemorrhage
phenytoin in the healing of clean surgical wounds

Conditions: Wound; Re-Epithelialization

Summary: the purpose of this study is to investigate the potential healing properties of phenytoin. the investigators will use the donor site of a split skin thickness graft (sstg) to model a basic wound in a randomized controlled trial of topical phenytoin against current best clinical practice. the investigators aim to demonstrate a dose dependent effect. the investigators hypothesis, based on previous clinical experience at our center and on current available literature, that phenytoin will reduce wound healing time.


Eligibility criteria:
inclusion criteria: * undergoing split thickness skin graft during trial time period at children's surgical centre exclusion criteria:

Keywords: phenytoin skin graft donor site clean surgical site wound model
study to assess efficacy and safety of two regimens of crisaborole ointment 2% in japanese participants aged ≥2 years with mild to moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a phase 2b, multi-center, randomized, double-blind, vehicle-controlled, intraparticipant study to evaluate efficacy and safety of two regimens of crisaborole ointment 2% in japanese pediatric and adult participants (cohort 1: 12 years and older, cohort 2: 2 to under 12 years old) with mild to moderate atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: * male or female participants ages; cohort 1: 12 years and older at the time of consent. cohort 2: 2 years to under 12 years old at the time of consent. * has confrimed clinical diagnosis of active ad according to hanifin and rajka criteria and has at least 6 months history prior to screening and has been clinically stable for more than 1 month * has at least 1% and no more than 30% bsa at baseline/day1, excluding scalp, genitals and groin area * has a investigator's static global assessment (isga) score of mild (2) or moderate (3) on day 1. exclusion criteria: * has other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. * participants had previous treatment with any topical or systemic pde-4 inhibitor.
procedures and follow-up of percutaneous tracheostomy in intensive care unit

Conditions: Acute Respiratory Failure; Neurological Disease; Heart Failure

Summary: tracheostomy is worldwide performed in intensive care unit (icu). according to the current literature, indication for percutaneous tracheostomy (pdt) in icu are: difficult prolonged weaning, prolonged mechanical ventilation, loss of airway reflex, copious secretions, upper airway obstruction. many studies have focused on the comparison between different pdt techniques and complication. the aim of our study is to evaluate the procedural features, complications, icu mortality, quality of life, post-discharge mortality of patients undergoing different pdt techniques performed in icu.


Eligibility criteria:
inclusion criteria: * age \>18 * indication for tracheostomy exclusion criteria: * infectious disease of neck

Keywords: percutaneous tracheostomy intensive care unit ineffective airway clearance weaning failure